151 related articles for article (PubMed ID: 25968438)
1. Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.
Peltenburg NC; Bakker JA; Vroemen WH; de Knegt RJ; Leers MP; Bierau J; Verbon A
Clin Chem Lab Med; 2015 Nov; 53(12):2021-9. PubMed ID: 25968438
[TBL] [Abstract][Full Text] [Related]
2. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A
Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861
[TBL] [Abstract][Full Text] [Related]
3. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ;
Hepatology; 2014 Jun; 59(6):2152-60. PubMed ID: 24449403
[TBL] [Abstract][Full Text] [Related]
4. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
Amjed S; Saleem HGM; Ullah S; Latif S; Shabana ; Jafar J; Waqar AB
BMC Infect Dis; 2024 Mar; 24(1):301. PubMed ID: 38468199
[TBL] [Abstract][Full Text] [Related]
5. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
[TBL] [Abstract][Full Text] [Related]
6. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.
Rembeck K; Waldenström J; Hellstrand K; Nilsson S; Nyström K; Martner A; Lindh M; Norkrans G; Westin J; Pedersen C; Färkkilä M; Langeland N; Buhl MR; Mørch K; Christensen PB; Lagging M
Hepatology; 2014 Jun; 59(6):2131-9. PubMed ID: 24519039
[TBL] [Abstract][Full Text] [Related]
7. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
[TBL] [Abstract][Full Text] [Related]
8. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Thompson AJ; Fellay J; Patel K; Tillmann HL; Naggie S; Ge D; Urban TJ; Shianna KV; Muir AJ; Fried MW; Afdhal NH; Goldstein DB; McHutchison JG
Gastroenterology; 2010 Oct; 139(4):1181-9. PubMed ID: 20547162
[TBL] [Abstract][Full Text] [Related]
9. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
[TBL] [Abstract][Full Text] [Related]
10. ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
Coppola N; De Pascalis S; Messina V; Di Caprio G; Martini S; de Stefano G; Starace M; Stornaiuolo G; Stanzione M; Ascione T; Minichini C; Sangiovanni V; Zampino R; Calò F; Rinaldi L; Persico M; Federico A; Buonomo AR; Borgia G; Gaeta GB; Filippini P; Gentile I
Antivir Ther; 2017; 22(7):551-558. PubMed ID: 28165327
[TBL] [Abstract][Full Text] [Related]
11. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.
Nyström K; Wanrooij PH; Waldenström J; Adamek L; Brunet S; Said J; Nilsson S; Wind-Rotolo M; Hellstrand K; Norder H; Tang KW; Lagging M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045981
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A
Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220
[TBL] [Abstract][Full Text] [Related]
13. Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.
Delvaux N; Costa VD; Costa MM; Villar LM; Coelho HS; Esberard EB; Flores PP; Brandão-Mello CE; Villela-Nogueira CA; Almeida AJ; Lampe E
Mem Inst Oswaldo Cruz; 2015 Aug; 110(5):636-43. PubMed ID: 26154744
[TBL] [Abstract][Full Text] [Related]
14. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.
Ochi H; Maekawa T; Abe H; Hayashida Y; Nakano R; Kubo M; Tsunoda T; Hayes CN; Kumada H; Nakamura Y; Chayama K
Gastroenterology; 2010 Oct; 139(4):1190-7. PubMed ID: 20637204
[TBL] [Abstract][Full Text] [Related]
15. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
DʼAvolio A; Ciancio A; Siccardi M; Smedile A; Baietto L; Simiele M; Marucco DA; Cariti G; Calcagno A; de Requena DG; Sciandra M; Cusato J; Troshina G; Bonora S; Rizzetto M; Di Perri G
Ther Drug Monit; 2012 Apr; 34(2):165-70. PubMed ID: 22406654
[TBL] [Abstract][Full Text] [Related]
16. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
Scherzer TM; Stättermayer AF; Stauber R; Maieron A; Strasser M; Laferl H; Schwarzer R; Datz C; Rutter K; Beinhardt S; Steindl-Munda P; Hofer H; Ferenci P
J Hepatol; 2013 Nov; 59(5):964-71. PubMed ID: 23850877
[TBL] [Abstract][Full Text] [Related]
17. ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
Asselah T; Zeuzem S; Soriano V; Bronowicki JP; Lohse AW; Müllhaupt B; Schuchmann M; Bourlière M; Buti M; Roberts SK; Gane EJ; Stern JO; Voss F; Baum P; Gallivan JP; Böcher WO; Mensa FJ
PLoS One; 2015; 10(12):e0144004. PubMed ID: 26650626
[TBL] [Abstract][Full Text] [Related]
18. ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.
Maan R; van der Meer AJ; Brouwer WP; Plompen EP; Sonneveld MJ; Roomer R; van der Eijk AA; Groothuismink ZM; Hansen BE; Veldt BJ; Janssen HL; Boonstra A; de Knegt RJ
PLoS One; 2015; 10(10):e0139317. PubMed ID: 26441325
[TBL] [Abstract][Full Text] [Related]
19. Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Matsuura K; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Tokunaga K; Mizokami M; Izumi N
J Med Virol; 2013 Mar; 85(3):449-58. PubMed ID: 23297176
[TBL] [Abstract][Full Text] [Related]
20. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
Naggie S; Rallon NI; Benito JM; Morello J; Rodriguez-Novoa S; Clark PJ; Thompson AJ; Shianna KV; Vispo E; McHutchison JG; Goldstein DB; Soriano V
J Infect Dis; 2012 Feb; 205(3):376-83. PubMed ID: 22158703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
